Data from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

• DOI: 10.1158/1535-7163.c.7311494.v1
• Publication Date: 2024-07-02T11:09:42Z
• Authors: Funda Meric-Bernstam; Michael W. Lloyd; Soner Koc; Yvonne A. Evrard; Lisa M. McShane; Michael T. Lewis; Kurt W. Evans; Dali Li; Lawrence Rubinstein; Alana Welm; Dennis A. Dean; Anuj Srivastava; Jeffrey W. Grover; Min J. Ha; Huiqin Chen; Xuelin Huang; Kaushik Varadarajan; Jing Wang; Jack A. Roth; Bryan Welm; Ramaswamy Govinden; Li Ding; Salma Kaochar; Nicholas Mitsiades; Luis Carvajal-Car...; Meenhard Herylyn; Michael A. Davies; Geoffrey I. Shapiro; Ryan Fields; Jose G. Trevino; Joshua C. Harrell; James H. Doroshow; Jeffrey H. Chuang; Jeffrey A. Moscow

<div>Abstract<p>Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to <i>in vivo</i> tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for <i>in vivo</i> growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.</p></div>